dc.contributor.author | Borralleras, Cristina | |
dc.contributor.author | Castrodeza Sanz, Javier | |
dc.contributor.author | Cámara Hijón, Carmen | |
dc.contributor.author | Eiros, José Mª | |
dc.contributor.author | Fernández-Prada, María | |
dc.contributor.author | Gil de Miguel, Ángel | |
dc.contributor.author | Mirada Masip, Gloria | |
dc.contributor.author | Moraga-Llop, Fernando | |
dc.contributor.author | Ocaña Rodríguez, Daniel | |
dc.contributor.author | Puig-Barberà, Joan | |
dc.contributor.author | Vázquez, Jorge | |
dc.contributor.author | Vergara-Alert, Júlia | |
dc.contributor.author | de Cambra, Salomé | |
dc.contributor.other | Producció Animal | ca |
dc.date.accessioned | 2024-01-31T09:05:01Z | |
dc.date.available | 2024-01-31T09:05:01Z | |
dc.date.issued | 2023-06-12 | |
dc.identifier.citation | Borralleras, Cristina, José Antonio Sanz, Pilar Arrazola, Carmen Cámara Hijón, José María Eiros, María Fernández-Prada, Ángel Gil De Miguel, et al. 2023. “The PHH-1V HIPRA Vaccine: A New Tool in the Vaccination Strategy against COVID-19.” Revista Española de Quimioterapia. 36 (5): 507–515. doi:10.37201/req/046.2023. | ca |
dc.identifier.issn | 0214-3429 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12327/2768 | |
dc.description.abstract | Objectives. Vaccination against SARS-CoV-2 is essential
to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to
an endemic phase. Vaccines are now required that offer broad,
long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here
we present a review of the evidence base for a new COVID-19
vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U),
and the results of an expert consensus.
Materials and methods. The expert committee consisted
of Spanish experts in medicine, family medicine, paediatrics,
immunology, microbiology, nursing, and veterinary medicine.
Consensus was achieved using a 4-phase process consisting of
a face-to-face meeting during which the scientific evidence
base was reviewed, an online questionnaire to elicit opinions
on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation,
vaccine programmes and the scientific evidence for PHH-1V
and a final face-to-face meeting at which consensus was
achieved.
Results. The experts agreed that PHH-1V constitutes a
valuable novel vaccine for the development of vaccination
programmes aimed towards protecting the population from
SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and
emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage
appropriate for global uptake.
Conclusions- The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V
confirm the appropriateness of this new COVID-19 vaccine. | ca |
dc.format.extent | 9 | ca |
dc.language.iso | eng | ca |
dc.publisher | Sociedad Española de Quimioterapia | ca |
dc.relation.ispartof | Revista Española de Quimioterapia | ca |
dc.rights | Attribution-NonCommercial 4.0 International | ca |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.title | The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19 | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 619 | ca |
dc.identifier.doi | http://www.doi.org/10.37201/req/046.2023 | ca |
dc.contributor.group | Sanitat Animal | ca |